PureTech Health Announces Collaboration with Boehringer Ingelheim to Advance Immuno-oncology Product Candidates using its Lymphatic Targeting Platform

PureTech Health to receive up to $26 million in upfront payments,
research support, and preclinical milestones and is eligible to
potentially receive more than $200 million in milestones, in addition to
royalties

Collaboration will initially focus on developing Boehringer
Ingelheim’s novel immuno-oncology product candidates

BOSTON–(BUSINESS WIRE)–PureTech Health plc (LSE: PRTC) (“PureTech Health”), an advanced
biopharmaceutical company developing novel medicines for dysfunctions of
the Brain-Immune-Gut (BIG) axis, today announced that it has entered
into a research collaboration with Boehringer Ingelheim to develop novel
product candidates for an undisclosed number of targets by leveraging
PureTech’s proprietary lymphatic targeting technology for immune
modulation. Under terms of the agreement, PureTech Health will receive
up to $26 million, including upfront payments, research support, and
preclinical milestones, and is eligible to receive more than $200
million in development and sales milestones, in addition to royalties on
product sales. The collaboration will initially focus on applying
PureTech’s lymphatic targeting technology to an immuno-oncology product
candidate designated by Boehringer Ingelheim.

“We see great promise in leveraging PureTech’s platform to target the
lymphatic system and deliver therapeutic candidates directly to the
lymph nodes responsible for priming, educating and proliferating immune
cells,” said Clive Wood, PhD, global head of discovery research at
Boehringer Ingelheim. “The approach is a potentially powerful tool for
modulating the immune system and may allow us to improve efficacy and
reduce systematic toxicities through precise targeting.”

The partnership leverages the potential of the proprietary lymphatic
targeting platform that PureTech Health is developing through its
internal R&D division. The approach harnesses the gut’s lipid transport
mechanisms to enable oral administration and transport of drug
candidates directly through the gut-draining lymphatic vasculature, also
bypassing first pass metabolism in the liver. More specifically, the
therapeutic candidates are directed to the mesenteric lymph nodes, which
program as many as 70 percent of circulating adaptive immune cells. By
targeting the lymphatic system directly, the technology has the
potential to achieve more effective and precise immunomodulation of
local tissues, while sparing the patient from the risks of extensive
systemic exposure to the drug. PureTech’s lymphatic targeting approach,
which is based on the research of Chris Porter, PhD, Director of the
Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University,
can potentially be applied to therapeutic molecules across a range of
physiochemical properties and holds promise for the development of novel
therapeutics for gastrointestinal, central nervous system, and
autoimmune diseases as well as cancer.

“This collaboration signals the exciting potential of another
proprietary platform from our internal R&D to enable novel immunotherapy
approaches by harnessing the lymphatic system’s capacity for immune cell
trafficking and immunomodulation,” said Daphne Zohar, co-founder and
chief executive officer of PureTech Health. “We look forward to working
with the excellent scientific teams at Boehringer Ingelheim to advance
this important program, which has the potential to greatly expand
therapeutic options for patients with cancer.”

The research collaboration with Boehringer Ingelheim will focus first on
using this approach to administer an immuno-oncology candidate for
gastrointestinal (GI) cancers directly to the gut lymphatics. About 70
percent of immune cells reside in lymphatic tissues associated with the
GI tract, so targeting immunomodulatory agents with this approach could
potentially tune both systemic and local immunity. Once the product
candidates enter the development stage, Boehringer Ingelheim will assume
full responsibility for development and PureTech Health will be eligible
for various developmental and sales milestones in addition to royalties
on product sales.

About PureTech’s Lymphatic Targeting Platform
PureTech’s
proprietary lymphatic targeting platform is designed to the body’s
natural lipid transport mechanisms to enable the transport of drug
molecules directly into the lymphatic system when administered orally.
This pathway facilitates entry into the mesenteric lymph nodes, which
are crucial centers for immune cell priming, education and proliferation
in the GI tract. Targeting the lymphatic vasculature enables rational
design of therapeutics to modulate immunity in a tissue-specific manner
and minimize systemic toxicity due to global immunosuppression.
Preclinical data suggest PureTech’s lymphatic targeting platform could
potentially enable more efficacious and less toxic therapeutics
addressing cancer and inflammatory and autoimmune diseases. This
technology is based on the pioneering research of Professor Chris Porter
and his team at the Monash Institute of Pharmaceutical Sciences, Monash
University, who continue to collaborate with PureTech Health on the
program. All the relevant intellectual property associated with his work
on this technology is exclusively licensed to PureTech and is supported
by additional PureTech Health patents.

About PureTech Health
PureTech Health (LSE: PRTC) is an
advanced biopharmaceutical company developing BIG medicines for
dysfunctions of the Brain-Immune-Gut axis. The Company has gained deep
insights into the connection between these systems and the resulting
role in diseases that have proven resistant to established therapeutic
approaches. By harnessing this emerging field of human biology, PureTech
Health is developing new categories of medicines with the potential to
have great impact on people with serious diseases.

PureTech Health is advancing a rich pipeline of innovative therapies
with an unbiased, non-binary, and capital efficient R&D model across its
affiliates and its internal labs. PureTech’s affiliates include seven
clinical-stage platforms, including one product that has been cleared by
the U.S. Food and Drug Administration (FDA) and a second product
candidate that has been filed with the FDA for review, and several other
novel preclinical programs. The PureTech Health pipeline includes
ground-breaking platforms and therapeutic candidates that were developed
in collaboration with some of the world’s leading experts.

PureTech’s internal research and development is centered on
tissue-selective immunomodulation for the treatment of oncology,
autoimmune, and CNS-related disorders, with a near-term focus on
targeting newly-discovered, foundational immunosuppressive mechanisms in
oncology and novel approaches that harness the lymphatic infrastructure.

For more information, visit www.puretechhealth.com or
connect with us on Twitter @puretechh.

Forward Looking Statement
This press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company’s future prospects, developments
and strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from current expectations, including,
but not limited to, those risks and uncertainties described in the risk
factors included in the regulatory filings for PureTech Health plc.
These forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each forward-looking
statement speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company nor any
other party intends to update or revise these forward-looking
statements, whether as a result of new information, future events or
otherwise.

This announcement contains inside information for the purposes of
Article 7 of Regulation (EU) 596/2014.

Contacts

Investors
Allison Mead Talbot
+1 617 651 3156
[email protected]

EU
media
Ben Atwell, Rob Winder
+44 (0) 20 3727 1000
[email protected]

U.S.
media
Tom Donovan
+1 857 559 3397
[email protected]